Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

Panelists discuss how the Phase phase 3 CLEAR trial evaluates organ-specific progression patterns in advanced renal cell carcinoma to better understand the efficacy of lenvatinib plus pembrolizumab compared to with sunitinib and guide subsequent treatment strategies.

EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma

EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC

Now Viewing

EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

EP: 5.The Role of the Multidisciplinary Care Team in RCC

EP: 6.Exploring Standards of Care and Treatment Goals in Advanced Clear Cell RCC

Recent Videos